Results 131 to 140 of about 232,533 (233)
Inflammatory Bowel Disease: Mechanisms and Therapeutic Advances
MedComm, Volume 7, Issue 9, September 2026.Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, is a rising, multifactorial chronic disorder driven by dysregulated mucosal immunity in genetically susceptible individuals and influenced by environmental and microbial factors.
Andrea Papait +5 more
wiley +1 more source
MedComm, Volume 7, Issue 9, September 2026.Microbial signals from gut and tumor‐resident bacteria, fungi, viruses, and bacteriophages reshape immune and metabolic networks within the tumor microenvironment, thereby influencing cancer progression, treatment response. Therapeutic modulations, including dietary interventions, probiotics, antibiotics, fecal microbiota transplantation, engineered ...
Juan Lu +8 more
wiley +1 more source
Multiplex PCR to Diagnose Gastrointestinal Infections: Key Limitations in Interpretation
United European Gastroenterology Journal, Volume 14, Issue 7, September 2026.ABSTRACT Multiplex polymerase chain reaction (PCR) panels are increasingly used for the evaluation of acute diarrhea, providing rapid and sensitive detection of a broad range of enteric pathogens. However, their widespread adoption has created important interpretive challenges for clinicians.
Giannoula S. Tansarli, Ferric C. Fang
wiley +1 more source
Point of care tests for hospital-acquired infections (HAIs) : economic analysis report [PDF]
A number of clinical/disease areas have been prioritised by the Technology Strategy Board (TSB) and Department of Health (DH) for the DIIA Innovation Platform.
Szczepura, Ala, Osipenko, Leeza
core
Comprehensive Reviews in Food Science and Food Safety, Volume 25, Issue 5, September 2026.ABSTRACT Low water activity ingredients, including dried fruits, vegetables, herbs, and spices, are widely used in ready‐to‐eat (RTE) and non‐RTE foods. Although low water activity limits microbial growth, bacterial pathogens can survive for extended periods in these products.
Heidy M. W. den Besten +7 more
wiley +1 more source
Clostridium difficile: a XXI. század nagy epidemiológiai kihívása
, 2015 A Clostridium difficile napjainkban leggyakrabban előforduló enterális patogén. Gram- pozitív, spóraképző, anaerob pálca. Enterotoxikus A és cytotoxikus B toxint termel. A C.
Molnár, Csilla
core
Delayed Loop Ileostomy Reversal Increases the Risk of Colitis and Clostridium difficile Infection
ANZ Journal of Surgery, Volume 96, Issue 9, Page 2658-2664, September 2026.Delayed loop ileostomy reversal is associated with increased post‐operative complications specifically colitis and Clostridium difficile colitis. The COVID‐19 pandemic caused a significant delay in ileostomy reversal timing. ABSTRACT Background Temporary loop ileostomy formation is a routine procedure performed to protect distal colorectal anastomosis.
Yan S. Tan +12 more
wiley +1 more source
Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy
Alimentary Pharmacology &Therapeutics, Volume 64, Issue 6, Page 729-747, September 2026.The gut microbiome modulates ulcerative colitis pharmacotherapy through microbial drug metabolism, immune regulation and altered drug bioavailability. Microbial composition influences response to aminosalicylates, corticosteroids, immunomodulators, biologics and small molecules, while microbiome‐targeted therapies show emerging promise.
Kate Collins +6 more
wiley +1 more source
, 2013 Summary Clostridium difficile infection (CDI) results in a wide spectrum of illness ranging from mild diarrhoea to severe colitis. CDI is associated with receiving healthcare and antibiotic use.
Clostridium difficile Sub ‐ Committee
core
Equine Veterinary Journal, Volume 58, Issue 5, Page 1363-1371, September 2026.Abstract Background Current treatment options for equine gastric ulcer syndrome (EGUS), such as omeprazole—a proton pump inhibitor (PPI)—have notable limitations, including the need for administration on an empty stomach. Potassium‐competitive acid blockers (P‐CABs), such as vonoprazan, are a newer class of acid suppressants that offer several ...
Camilo J. Morales +4 more
wiley +1 more source